CAS 148553-50-8

About the API

Trade name(s) Lyrica
Technology Synthetic Organic Chemistry
Molecular Formula C8H17NO2
Molecular Weight 159.2261 g/mol
Therapeutic category Epileptic
Available formulations Oral Liquid Oral Solid Oral Solid Long-Acting
Regulations Canada DMF Flag Canada DMF CEP Flag CEP EU DMF Flag EU DMF Japan DMF Flag Japan DMF Korea DMF Flag Korea DMF US DMF Flag US DMF

General Information

Pregabalin is used to manage neuropathic pain (pain associated with nerve damage) and postherpetic neuralgia (a painful complication of shingles), and as adjunctive therapy for adult patients with partial onset seizures (epileptic fits starting in one specific part of the brain).


In addition, it is used to treat fibromyalgia (a disorder characterized by widespread musculoskeletal pain) and treatment of generalized anxiety disorder, according to country. Administered as an oral tablet or solution, pregabalin is the first FDA-approved drug for fibromyalgia. In the US, its use for neuropathic pain is limited to peripheral pain associated with diabetes.


Pregabalin is being studied for the alleviation of pain in a wide range of conditions. It is a Schedule V controlled substance according to the US Controlled Substances Act (i.e., lowest potential for abuse).


Pregabalin was approved in the US and the EU in 2004. In 2007, the FDA approved its use for fibromyalgia. It is prepared through multi-step chemical synthesis.